Trial of moxifloxacin-containing triple therapy after initial and second-line treatment failures for Helicobacter pylori infection

Jae Hee Cheon, Nayoung Kim, Dong Ho Lee, Jin Wook Kim, Jin Hyeok Hwang, Young Soo Park, Jung Mogg Kim, Seong O. Suh, Hyun Chae Jung, In Sung Song

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

BACKGROUND/AIMS: Proton-pump inhibitor (PPI)-based triple therapy for Helicobacter pylori eradication is widely used with considerable failure rate. Bismuth-based, second-line therapy is also associated with failures in more than 20% of cases in Korea. Our aim was to evaluate the efficacy and tolerability of third-line therapy containing moxifloxacin as a rescue in Korea. METHODS: The subjects consisted of 201 patients infected with H. pylori, who were treated with PPI-based therapy, 42 patients treated with bismuth-based after failure of initial PPI triple therapy, and 10 patients treated with moxifloxacin-containing triple therapy after failure of successive initial and second-line therapy. Eradication rate, compliance and side effect rates were compared. RESULTS: The eradication rates of initial, second-line, and third-line therapy were as follows: 67.2%/83.3%, 54.8%/76.7%, 80.0%/88.9% by intention-to-treat and per protocol analysis, respectively. The compliance of patients for each treatment was 98.2%, 90.9%, 100%, respectively. The side effect rate was significantly higher in the bismuth triple therapy than in the PPI- or moxifloxacin-containing triple therapy (p<0.05). CONCLUSIONS: Moxifloxacin-containing triple therapy shows high eradication rate with fewer side effects and good compliance. Thus, this regimen could be used as a rescue therapy.

Original languageEnglish
Pages (from-to)111-117
Number of pages7
JournalThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
Volume45
Issue number2
Publication statusPublished - 2005 Feb

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'Trial of moxifloxacin-containing triple therapy after initial and second-line treatment failures for Helicobacter pylori infection'. Together they form a unique fingerprint.

  • Cite this

    Cheon, J. H., Kim, N., Lee, D. H., Kim, J. W., Hwang, J. H., Park, Y. S., Kim, J. M., Suh, S. O., Jung, H. C., & Song, I. S. (2005). Trial of moxifloxacin-containing triple therapy after initial and second-line treatment failures for Helicobacter pylori infection. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 45(2), 111-117.